[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Westat\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":198},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,52,79,109,123,155,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100054059","phase-2-combatting-hiv-or-other-stis-early-choose-100054059",false,"NCT07510048","Combatting HIV Or Other STIs Early (CHOOSE)","Combatting HIV Or Other STIs Early (CHOOSE): An Integrated Strategy of Pre-Exposure Prophylaxis (PrEP) Mobile Health (mHealth) Support and Doxycycline Post-Exposure Prophylaxis (DoxyPEP)","CHOOSE","Inclusion Criteria\n\n* Age 13-24 years, inclusive;\n* Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime;\n* Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package;\n* Not currently on PrEP and interested in learning more about PrEP;\n* Is not living with HIV;\n* Weighs at least 35 kg;\n* Willing to receive PrEP care from a provider at a participating ATN SC;\n* Able to understand, read, and speak English;\n* Able to participate at the study site; and\n* Willing and able to provide written informed consent.\n* If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation.\n* If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation.\n\nExclusion Criteria:\n\n* Female;\n* In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months;\n* Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study);\n* Plan to move within 18 months to an area inaccessible to a participating ATN SC;\n* An employee of the participating SC; or\n* Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team.\n* Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results.",true,"MALE","13 Years","24 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people. It is hypothesized that PrEP Choice will improve HIV PrEP uptake and adherence among young people and will be cost-effective to deliver to young people in the United States (U.S.). This study will also assess the uptake, adherence, and acceptability of DoxyPEP among young people.",[29,30,31,32],"HIV","STIs","STIs Prevention","HIV Prevention",[29,30,34,35,36,37,38],"sexually transmitted infection","PrEP","DoxyPEP","mobile health","mHealth","NOT_YET_RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":23},"2026-07-20",{"date":47,"type":23},"2029-03-30",{"name":49,"class":50},"Westat","OTHER",6,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":60,"minAge":19,"maxAge":20,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100053662","linking-youth-to-pre-exposure-prophylaxis-prep-services-100053662","NCT07438041","Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services","Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services (LYPS): An Innovative Mobile Delivery and Mobile Health (mHealth) Intervention to Optimize PrEP Adherence and Persistence","LYPS","Inclusion Criteria:\n\n* Age 13-24 years, inclusive;\n* Reports anal or vaginal sex in the past year;\n* Is not living with HIV;\n* Weighs at least 35 kilograms (77 pounds);\n* Willing to receive PrEP care from a provider at a participating SC either in the clinic or at one of the designated places in the community being offered by the SC SC;\n* Has an Android-based smartphone or iPhone;\n* Has fluency in English (able to read, speak, and understand English); and\n* Willing to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Has counter-indications for PrEP according to guidelines and approved local label;\n* Has any clinically significant systemic disease (including but not limited to significant or uncontrolled liver disease, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis, or bone disease) or diabetes;\n* Any other medical, behavioral, or other conditions that, in the opinion of the SC project lead or designee, could interfere with adherence to study procedures or compromise interpretation of study results;\n* Concurrent participation in ATN 166, ATN 170, or any other clinical trial providing HIV medications (PrEP, vaccine, etc.) or currently receiving any PrEP-adherence or persistence behavioral intervention; or\n* Is currently incarcerated or pending incarceration.","ALL",{"count":62,"type":23},272,[64],"NA","The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.",[29,35,67],"PrEP Adherence",[35,69,70,71],"Adherence","Oral PrEP","Injectable cabotegravir",{"date":42,"type":43},{"date":74,"type":23},"2026-07-27",{"date":76,"type":23},"2028-12-15",{"name":49,"class":50},4,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":60,"minAge":87,"maxAge":20,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100550229","behavioral-activation-and-risk-reduction-for-stimulant-use-among-sexually-active-adolescents-and-young-adults-100550229","NCT06444360","Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young Adults","Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Adolescents and Young Adults (Project IMPACT)","IMPACT","Inclusion Criteria:\n\n* Age 16-24 years, inclusive, at enrollment\n* Male or female\n* Self-reports condomless anal or vaginal sex while using stimulants (5 hour prior to, or during sex) within the last 4 months; stimulants is defined as crystal methamphetamine, cocaine, and MDMA (e.g., ecstasy, molly)\n* Willing and able to provide written informed consent for study participation\n* Access to a computer\u002Fsmartphone\u002Ftablet that can use video chat (e.g., Zoom or Google Meet)\n* Provide a mailing address where they can receive a package\n* Access to stable internet that they can use for more than 2 hours at a time\n* Have a private place (where no one else can see or hear) where they can complete visits online\n* Reside within the continental U.S.\n\nExclusion Criteria:\n\n* Unable to provide informed consent due to severe mental or physical illness\n* Concurrent enrollment in another HIV prevention or treatment study (enrollment in a substance treatment program is acceptable)\n* Randomized to IMPACT arm prior to March 2025 study stop\n* Non-English-speaking\n* Is currently incarcerated or pending incarceration\n* Is currently pregnant or planning to become pregnant\n* Any other medical condition, medical\u002Fbehavioral intervention, or other condition that, in the opinion of the Project Lead or designee, could interfere with the safety of participants or staff, adherence to study procedures, or compromise interpretation of study results","16 Years",{"count":89,"type":23},360,[64],"The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk.",[29],[94,95,96,97,98],"Behavioral Activation","risk reduction","intervention","stimulant use","HIV sexual risk reduction","RECRUITING","2026-06-15",{"date":102,"type":43},"2026-06-17",{"date":104,"type":43},"2025-11-04",{"date":106,"type":23},"2029-06-30",{"name":49,"class":50},2,{"id":110,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":112,"briefSummary":27,"conditions":113,"keywords":114,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":51},"100632158",{"count":22,"type":23},[26],[29,30,31,32],[29,30,34,35,36,37,38],"2026-05-19",{"date":117,"type":43},"2026-05-22",{"date":119,"type":23},"2026-04",{"date":121,"type":23},"2029-09",{"name":49,"class":50},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":24,"phases":134,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100572833","phase-4-doxycycline-prophylaxis-for-prevention-of-sexually-transmitted-infections-100572833","NCT06738407","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States","Inclusion Criteria:\n\n* Age 13-29 years, inclusive;\n* Self-reports GC, CT, and\u002For early syphilis diagnosis in the 12 months prior to screening;\n* Self-reports condomless (oral, vaginal, and\u002For anal) intercourse at least once in the 30 days prior to screening\n* Is at least 45 kilograms (99.2 pounds) in weight\n* Fluent in English (able to read, speak, and understand English);\n* Willing to undergo all required study procedures; and\n* Willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Is male;\n* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;\n* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;\n* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;\n* Current or planned use of doxycycline for a prolonged period (\\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;\n* Prolonged antibiotic use (\\> 2 weeks) within the last 30 days prior to enrollment;\n* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;\n* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or\n* Any other medical condition, medical\u002Fbehavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)\u002FInvestigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results.","FEMALE","29 Years",{"count":133,"type":23},760,[135],"PHASE4","The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.",[138,139,140,141],"Gonorrhea","Chlamydia","Syphilis","Sexually Transmitted Infections (STIs)",[143,30,144,145],"Sexually Transmitted Infections","Doxycycline Prophylaxis","Doxycycline","2026-05-12",{"date":148,"type":43},"2026-05-15",{"date":150,"type":43},"2026-02-27",{"date":152,"type":23},"2028-06-15",{"name":49,"class":50},13,{"id":156,"slug":4,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":60,"minAge":19,"maxAge":20,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":158,"briefSummary":65,"conditions":159,"keywords":160,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":78},"100626623",{"count":62,"type":23},[64],[29,35,67],[35,69,70,71],"2026-04-15",{"date":163,"type":43},"2026-04-16",{"date":165,"type":23},"2026-05",{"date":167,"type":23},"2028-12",{"name":49,"class":50},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":60,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":181,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100634767","cohort-of-repeat-donor-experiences-core-study-100634767","NCT07543965","Cohort of Repeat Donor Experiences (CORE) Study","Associations Between Frequent Plasmapheresis, Biomarkers, and Health Outcomes: A 2-Year National Prospective Cohort Study","CORE","Inclusion Criteria:\n\n* Aged 18-74;\n* Meet health and medical history requirements for being a plasma donor per eCFR::21 CFR 630.10 Subpart B -- General donor eligibility requirements;\n* Willing to provide phone number and mailing address; has access to internet-enabled smartphone device;\n* Plans to remain within local area during study duration; has not donated whole blood within past 12 months;\n* Does not have permanent deferral;\n* Has not donated plasma more than once at a non-participating plasma center;\n* Another member of their household is not enrolled.","18 Years","74 Years",{"count":180,"type":23},2090,"OBSERVATIONAL","The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (anticipated to begin in summer 2026) and up to 3 months during the pilot launching in mid-March 2026. This study aims to confirm a lack of negative health effects Source Plasma donors may experience as a result of frequent plasmapheresis. The study will use data obtained through self-report surveys for the duration of the study along with periodic whole blood sample collections to test for CRP, ferritin, and IgG.",[184],"Health Effects (Ferritin Levels, CRP Levels, iGg Levels, Self-reported Health)",[186,187,188],"plasma","plasma-derived therapies","pharma","2026-04-14",{"date":191,"type":43},"2026-04-22",{"date":193,"type":23},"2026-04-06",{"date":195,"type":23},"2029-04-30",{"name":49,"class":50},1,""]